Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6736653 | 0.85 | MEN1 (0.41) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL15564880 | 0.81 | FFAR3 (0.40) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL13818123 | 0.78 | FFAR3 (0.31) | — | |
| SCHEMBL12632703 | 0.78 | NPSR1 (0.35) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL25616533 | 0.76 | FFAR3 (0.50) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL283125 | 0.76 | — | — | |
| SCHEMBL8175853 | 0.76 | FFAR3 (0.50) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL25616531 | 0.76 | FFAR3 (0.50) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL21503963 | 0.76 | MEN1 (0.36) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL17893308 | 0.75 | FFAR3 (0.43) | MEN1KMT2ANPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346612-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | US | disclosed |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB Biopharma SRL (BE) | 2025-04-24 | — | — | US | disclosed |
| CN-119630670-A | Modulators of TNFalpha activity and uses thereof | 瑞雷拉公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025038927-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2023183757-A2 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230250105-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | SANOFI (FR) | 2023-08-10 | — | — | US | disclosed |
| EP-3615534-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-09-15 | — | — | EP | disclosed |
| US-20210252012-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | SANOFI (FR) | 2021-08-19 | — | — | US | disclosed |
| US-20210252012-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | SANOFI (FR) | 2021-08-19 | — | — | US | disclosed |
| US-10980814-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-04-20 | — | — | US | disclosed |
| US-10980814-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-04-20 | — | — | US | disclosed |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-03-23 | — | — | US | disclosed |
| US-20200046723-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | SANOFI (FR) | 2020-02-13 | — | — | US | disclosed |
| US-20200046723-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | SANOFI (FR) | 2020-02-13 | — | — | US | disclosed |
| CN-110582495-A | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2019-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | MEN1 4221/4885KMT2A 4796/4885NPSR1 3259/4885 |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | MEN1 4221/4885KMT2A 4796/4885NPSR1 3259/4885 |
| US-20250346612-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | LSS, PAICS, BLVRB | MEN1 116/4885KMT2A 3979/4885NPSR1 1109/4885 |
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | BMP2, BMP4, DCX | MEN1 3898/4885KMT2A 1995/4885NPSR1 992/4885 |
| US-20200046723-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | MEN1 2491/4885KMT2A 4596/4885NPSR1 2524/4885 |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | MEN1 3148/4885KMT2A 4423/4885NPSR1 2940/4885 |
| US-20230250105-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | MEN1 2491/4885KMT2A 4596/4885NPSR1 2524/4885 |
| US-10980814-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | MEN1 2059/4885KMT2A 4584/4885NPSR1 852/4885 |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | MEN1 2491/4885KMT2A 4596/4885NPSR1 2524/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | MEN1 4221/4885KMT2A 4796/4885NPSR1 3259/4885 |
| US-20210252012-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | MEN1 2491/4885KMT2A 4596/4885NPSR1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.